Related Experiment Video

Updated: Mar 1, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K

Value-Based Medicine and Integration of Tumor Biology

Gabriel A Brooks1, Linda D Bosserman1, Isa Mambetsariev1

  • 1From the Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH; City of Hope Comprehensive Cancer Center, Duarte, CA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 1, 2017
PubMed

Insights

The genomic revolution in cancer care offers targeted therapies and improved patient outcomes. However, rising costs necessitate value-based strategies for sustainable personalized cancer medicine.

Area of Science:

  • Oncology
  • Genomics
  • Health Economics

Background:

  • The field of clinical oncology is undergoing a significant transformation driven by molecular insights and genomic discoveries.
  • This revolution has led to the development of novel genomically targeted therapies, improving patient outcomes.
  • However, the increasing costs associated with these advanced treatments pose challenges to healthcare systems.

Purpose of the Study:

  • To explore the impact of the genomic revolution on cancer care delivery.
  • To examine frameworks for evaluating the value of genomically targeted therapies.
  • To outline strategies for implementing value-based cancer care.

Main Methods:

  • Literature review and synthesis of current research on genomic oncology and health economics.
  • Analysis of frameworks for value assessment in targeted cancer therapies.
  • Identification of practical solutions for value-based care implementation.

Main Results:

  • Genomic insights are redefining cancer biology and driving the development of targeted therapies.
  • The rising cost of cancer care, particularly targeted therapies, highlights the need for value-based approaches.
  • Improved patient outcomes are increasingly linked to personalized, genomically informed treatment strategies.

Conclusions:

  • The genomic revolution in oncology necessitates a shift towards value-based care to ensure sustainability and accessibility.
  • Implementing evidence-based pathways, biomarker development, and team-based care are crucial for maximizing the value of targeted therapies.
  • Addressing the practical challenges of cost and value is essential for realizing the full promise of personalized cancer medicine.

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.3K
Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.6K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K